氯吡格雷抵抗基因多态性与PCI术后氯吡格雷抵抗的临床观察

摘要/Abstract

摘要： 目的观察氯吡格雷抵抗基因多态性与经皮冠状动脉介入术（percutaneous coronary intervention, PCI）术后氯吡格雷抵抗。方法接收PCI术后服用氯吡格雷的患者100例,并检测氯吡格雷快代谢、中代谢、慢代谢基因,对慢代谢型基因患者调整为替格瑞洛口服,随访1年并记录。结果 100例患者中CYP2C19快代谢型、中间代谢型和慢代谢型之间血小板抑制率差异有显著性（P<0.05）,ABCB1和PON1各基因型之间血小板抑制率的差异无显著性（P>0.05）。随访1年,中间代谢型氯吡格雷加倍口服,慢代谢型改为替格瑞洛口服,CYP2C19快代谢型、中间代谢型和慢代谢型,ABCB1携带TT、TC、CC等位基因、PON1携带AA、AG、GG等位基因患者临床终点事件差异无显著性（P>0.05）。结论冠心病患者PCI术后用药可依据氯吡格雷抵抗基因检测结果指导临床,具有可靠性。

李学香. 氯吡格雷抵抗基因多态性与PCI术后氯吡格雷抵抗的临床观察[J]. 心血管病防治知识, 2021, 11(5): 3-7.

参考文献

[1] 郑明,涂明义,郭宏伟,等.波立维联合拜阿司匹林治疗短暂性脑缺血发作/缺血性小卒中30例的临床效果分析[J] .内科, 2014, 9(1) : 26-27.
[2] Smith SC Jr,Feldman TE,Hirshfeld JW, et al.ACC/AHA/SCAI 2005guideline update for percutaneous coronary intervention :a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to Update the 2001Guidelines for Percutaneous Coronary Intervention)[J].J Am CollCardiol,2006,47(1):1-121.
[3] Furie KL,Kasner SE,Adams RJ,et al.Guidelines for the prevention of stroke in patients with stroke or transient is chemic attack : a guideline for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 2011,42(1):227-276.
[4] Yusuf S, Zhao F, Mehta SR, et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med,2001,345(7):494-502.
[5] Tolleson TR, Newby LK, Harrington RA, et al.Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)[J] Am J Cardio1,2003,92(3):330-333.
[6] Wang Y, Zhao X, Lin J, et al.Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack[J].JAMA,2016,316(1):70-78.
[7] Karazniewicz-Lada M,Danielak D,Rubi′S B,et al. The influence of genetic polymorphism of Cyp2c19isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases[J] ClinPharmacol,2014,54(8):874-880.
[8] Bliden KP, DiChiara J,Tantry US, et al. Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate[J]. Am Coll Cardiol, 2007,49(6) : 657-666.
[9] Abell LM, Liu EC.Dissecting the activation of thienopyridines by cytochromes P450 using a pharmaco dynamic assay in vitro[J]. J Pharmacol Exp Ther,2011,339(2): 589-596.
[10] Savi P,Herbert JM.Clopidogrel and ticlopidine:P2Y12aden-osine diphosphate-receptor antagonists for the prevention of atherothrombosis[J].Semin Thromb Hemost,2005,31(2):174-183.
[11] Savi P, Nurden P, Nurden AT, et al.Clopidogrel: a review of its mechanism of action[J]. Platelets, 1998, 9(3/4): 251-255.
[12] Sambu N,Curzen N.Monitoring the effectiveness of anti-platelet therapy: opportunities and limitations[J].Br J ClinPharmacol,2011,72(4):683-696.
[13] Zhang LN,Bai J,Li YR,et al.Thromboelastography vs light transmission aggregometry for platelet aggregation in acute coronary syndrome patients under dual antiplatelet therapy[J].Chin J Mult Organ Dis Elderly,2013,12(1):25-28.
[14] Simon T, Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med,2009,360(4):363-375.
[15] 谢诚,丁肖梁,杭永付,等.中国服用氯吡格雷冠心病患者CYP2C19基因多态性与血小板聚集抑制率相关性研究的系统评价[J].中国现代应用药学,2020,37(7):851-857.
[16] 段明勤,黄改荣,曹选超,等.CYP2C19基因型多态性与老年人冠状动脉介入术后氯吡格雷疗效的相关性[J].中华老年医学杂志,2016,35(9):948-950.
[17] 郭玉梅,张琳,李海洲,等.冠状动脉性心脏病合并高血压患者CYP2C19基因多态性及不同基因型与氯吡格雷抵抗的关系研究[J].中国实用医刊,2019(23):14-17.
[18] Hulot JS,Collet JP,Silvain J,et al.Cardiovascular risk in clopidogreltreated patients according to cytochrome P450 2C19*2loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis[J].J Am Coll Cardiol,2010,56(2):134-143.
[19] 李笑笑,吕佳宁,吴旭青,等.ABCB1和CYP2C19基因多态性与动脉粥样硬化性脑梗死患者氯吡格雷疗效的相关性[J].中国临床医学,2019,26(6):827-833.
[20] 关宏. 急性心肌梗死患者CYP2C19、ABCB1基因多态性与血小板抵抗的相关性分析[J].医学研究杂志,2018,47(12):149-153.
[21] 张丽,苗苗,刘俊.CYP2C19和ABCB1基因多态性及其在冠心病患者中差异性分布[J].临床合理用药杂志,2018,11(25):131-132,134.
[22] Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med,2009,360(4):363-375.
[23] 范洁,詹三华,袁孔现.经皮冠状动脉介入术术后病人CYP2C19*2、CYP2C19*3和PON1基因多态性与氯吡格雷血药浓度及疗效的相关性分析[J].安徽医药,2020,24(2):385-389.
[24] 辛宏,李程亮,蔡天志,等.PON-1基因多态性与PCI术后主要心血管事件相关性研究[J].陕西医学杂志,2017,46(4):417-418,425.
[25] 陆文岐,周月广,刘小畅,等.PON1(rs662)基因多态性对冠脉介入治疗患者血小板高反应性的影响[J].中国医院药学杂志,2017,37(14):1397-1400,1417.
[26] Chen DY,Wang CY,Wen MS,et al.Paraoxonase-1is not amajor determinant of stent thrombosis in a Taiwanese population[J].PLoS One,2012,7(6):39178.
[27] Bouman HJ,Sch mig E,van Werkum JW,et al.Paraoxo-nase-1is a major determinant of clopidogrel efficacy[J].NatMed,2011,17(1):110-116.
[28] Lu WQ,Zhou YG,Liu XC,et al.Association of PON1(rs662)gene polymorphism with high platelet reactivity inpost-PCI patients[J].Chin Hosp Pharm J,2017,37(14):1397-1400.
[29] Yang J,Zhou JS,Tan J,et al.Paraoxonase-1Q192Rpoly-morphism is not associated with clopidogrel response in Chinese stroke patients[J].Pharmazie,2012,67(12):1026-1029.
[30] Hasan MS,Basri HB,Hin LP,et al.Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention[J].Int J Neurosci,2013,123(3):143-154.
[31] Simon T,Verstuyft C,Mary-Krause M,et al.Cytochrome P-450 Polymorphisms and Response to Clopidogrel[J]. N Engl J Med,2009:363-375.
[32] Mao L,Jian C,Changzhi L,et al.Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects[J]. Arch Cardiovasc Dis,2013,106(10):517-527.